Massivemarkets

CRSP

CRISPR Therapeutics AG

Nasdaq · usd

$49.39-0.60 (-1.20%)
At close · 15-minute delayed
$49.35-0.04 (-0.08%)
As of 7:55:38 PM EDT on Oct 23, 2026 · After hours

CRISPR Therapeutics AG (CRSP) trades at $49.39 (-1.20%) as of 7:55:38 PM EDT on Oct 23, 2026, -11.33% over the past month. Market cap is $4.83B, with 9.6 days to cover in short interest.

Stock performance

How CRISPR Therapeutics AG (CRSP) stock has performed from one day to one year, with its 52-week range.

-0.22%
-$0.11 over 1D
$48.24$48.75$49.27$49.785:45 AM10:35 AM12:35 PM2:35 PM8:00 PM$49.60
1D
-1.20%
1W
+0.28%
1M
-11.33%
YTD
-5.82%
1Y
-24.85%
52-wk range
$44.12 – $67.73

Key statistics

Today's trading snapshot for CRSP: day range, open, previous close, volume and market cap.

Day range
$48.02 – $49.68
Open
$49.31
Prev close
$49.99
Volume
2.12M
Market cap
$4.83B
Shares out
96.69M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for CRISPR Therapeutics AG: P/E, P/S, P/B, ROE and more.

P/E
—
P/S
360.94
P/B
2.77
P/FCF
—
ROE
-25.8%
ROA
-17.0%
Debt/Equity
0.34
Div yield
0.00%

As of Oct 22, 2026

8-K filings

Material corporate events CRISPR Therapeutics AG has disclosed to the SEC on Form 8-K.

  • Executive leadershipOct 19, 2026

    On October 19, 2026, CRISPR Therapeutics AG announced the promotion of Andrew J. Silver, currently the Company's SVP, Finance, to be the Company's Chief Financial Officer effective immediately. Mr. Silver will also serve as the Company's principal financial officer and principal accounting officer.

  • Governance documentsJun 4, 2026

    On June 4, 2026, at the Annual Meeting, the shareholders of the Company approved amendments to the articles of association of the Company (the 'Articles of Association'). The Company's amended and restated Articles of Association become effective upon registration in the Commercial Register in the canton of Zug, Switzerland on or about June 5, 2026.

  • Debt activityMar 16, 2026

    On March 16, 2026, CRISPR Therapeutics AG (the "Company") completed its previously announced private offering (the "Offering") of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the "Notes"), including the exercise in full of the initial purchasers' option to purchase up to an additional $50.0 million principal amount of Notes. The investors in the Notes agreed to an effective coupon of 1.125%... The Notes are senior, unsecured obligations of the Company and will mature on March 1, 2031.

  • Debt activityMar 11, 2026

    On March 10, 2026, CRISPR Therapeutics AG (the "Company") issued a press release announcing that it had commenced a private offering, subject to market conditions and other factors, of $350.0 million aggregate principal amount of convertible senior notes due 2031 (the "notes") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. On March 11, 2026, the Company issued a press release announcing the pricing of an upsized offering of the notes, increasing the size of the offering to an aggregate principal amount of $550 million.

  • Material agreementsJan 12, 2026

    The Company has established a collaboration and clinical supply agreement with Eli Lilly to evaluate zugo-cel together with pirtobrutinib in aggressive B-cell lymphomas, further expanding the program's development in oncology.

CRSP short interest

How heavily CRSP is shorted: shares short, days to cover and average daily volume.

Days to cover
9.6
Short interest
18.68M
Avg volume
1.95M

As of · reported to FINRA twice monthly.

CRSP news

The latest news and headlines about CRISPR Therapeutics AG (CRSP).

Frequently asked questions

What is the CRISPR Therapeutics AG (CRSP) stock price today?

CRISPR Therapeutics AG (CRSP) is trading at $49.39 (-1.20% on the day) as of 7:55:38 PM EDT on Oct 23, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is CRISPR Therapeutics AG?

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for…

What is the short interest in CRSP?

As of Sep 30, 2026, CRSP has 18.68M shares short and 9.6 days to cover.

What exchange is CRSP listed on?

CRISPR Therapeutics AG (CRSP) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

Build with AI

Build an analysis of CRSP with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a CRSP analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Want the most up-to-date, real-time data? Connect to the Massive API and MCP server — the source behind every number on this page — covering stocks, options, indices, currencies and futures. Docs: https://massive.com/docs/rest. Get a free API key.

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.